Dry eye syndrome(DES)is a common disease causing by instable tear film induce ocular surface inflammation.In ophthalmological treatment,topical delivery of ocular therapeutics such as eye-drop is usually used,but ocular barrier of eyes can impede the release of pharmaceutical drugs,local bioavailability of the drug decreases.The main objective of the study is to develop a new nanomedicine for dry eyes syndrome treatment.Gelatin was adapted as the drug carrier with surface coating of hyaluronic acid(HA)to increase drug retention on the cornea.And the polyphenol,epigallocatechin gallate(EGCG),was encapsulated in the nanocarriers as the anti-inflammation agent to treat DES.These nanomedicine were abbreviated as GE and GEH,its particle size and zeta potential were about 142.1 ± 32.6,253.4 ± 7.3 nm and 23.2 ± 0.5,9.2 ± 1.8 mV.Benzalkonium chloride(BAC)at concentration of 0.1%was applied to the rabbit ocular surface for DES inducement.Then,the GE and GEH nanoparticles was used as an eye-drop to instilled in healthy and experimental dry eye rabbits.No ocular discomfort and irritation phenomenon were observed in rabbits after topical delivery of GEH formulation.In DES rabbits,both parameters significantly improved after GEH nanomedicine treatment.Anterior eye segment of treated rabbits showed normal architecture and morphology.Such as tear production and fluorescein staining.These results identify a potential application of EGCG-nanomedicine as a new therapeutic modality for the treatment of dry eye disease.